Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析

◆英語タイトル:Akari Therapeutics Plc (AKTX) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH141622FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥68,400見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥102,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company. The company is engaged in the development of therapeutic treatments for rare and orphan autoimmune and inflammatory diseases. It offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a and formation of C5b – 9. Akari’s pipeline products include paroxysmal nocturnal hemoglobinuria, Guillain Barre Syndrome and atypical hemolytic uremic syndrome. The pipeline products include LTB4+C5, Coversin, Coversin LA, , LTB4, LTBA LA, and bioamine inhibitors. It operates its business in Switzerland, Israel, the UK and the US. Akari is headquartered in London, Greater London, the UK.

Akari Therapeutics Plc Key Recent Developments

Feb 01,2021: Akari Therapeutics adds histamine inhibitor votucalis to pipeline to treat neuropathic Pain and dermatological disease
Dec 11,2020: Akari Therapeutics reports third quarter 2020 financial results and highlights recent clinical progress
Sep 01,2020: Akari Therapeutics reports second quarter 2020 financial results and highlights recent clinical progress
Jul 01,2020: Akari Therapeutics announces appointment of Chief Financial Officer
Mar 31,2020: Akari Therapeutics reports fourth quarter and full year 2019 financial results and business highlights

This comprehensive SWOT profile of Akari Therapeutics Plc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Akari Therapeutics Plc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Akari Therapeutics Plc – Key Information
Akari Therapeutics Plc – Overview
Akari Therapeutics Plc – Key Employees
Akari Therapeutics Plc – Key Employee Biographies
Akari Therapeutics Plc – Key Operational Heads
Akari Therapeutics Plc – Major Products and Services
Akari Therapeutics Plc – History
Akari Therapeutics Plc – Company Statement
Akari Therapeutics Plc – Locations And Subsidiaries
Akari Therapeutics Plc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Akari Therapeutics Plc – Business Description
Akari Therapeutics Plc – Corporate Strategy
Akari Therapeutics Plc – SWOT Analysis
SWOT Analysis – Overview
Akari Therapeutics Plc – Strengths
Akari Therapeutics Plc – Weaknesses
Akari Therapeutics Plc – Opportunities
Akari Therapeutics Plc – Threats
Akari Therapeutics Plc – Key Competitors

Section 3 – Company Financial Performance Charts

Akari Therapeutics Plc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Akari Therapeutics Plc, Key Information
Akari Therapeutics Plc, Key Ratios
Akari Therapeutics Plc, Share Data
Akari Therapeutics Plc, Major Products and Services
Akari Therapeutics Plc, History
Akari Therapeutics Plc, Key Employees
Akari Therapeutics Plc, Key Employee Biographies
Akari Therapeutics Plc, Key Operational Heads
Akari Therapeutics Plc, Other Locations
Akari Therapeutics Plc, Subsidiaries
Akari Therapeutics Plc, Key Competitors
Akari Therapeutics Plc, SWOT Analysis
Akari Therapeutics Plc, Ratios based on current share price
Akari Therapeutics Plc, Annual Ratios
Akari Therapeutics Plc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Akari Therapeutics Plc (AKTX):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Cerner Corp (CERN):企業の財務・戦略的SWOT分析
    Cerner Corp (CERN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Milo Biotechnology LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Milo Biotechnology LLC (Milo) is a biotechnology company that develops novel therapies based on follistatin, a protein that increases muscle mass and strength. The company’s pipeline product includes AAV1 (based on adeno-associated virus), which is a gene therapy for the one time treatment o …
  • Binex Co Ltd (053030):企業の財務・戦略的SWOT分析
    Summary Binex Co Ltd (Binex) is a provider of biologic and pharmaceutical products. The company provides products such as bisroot, digestive products, antispasmodic and antiulcer agents, NSAIDs, cardiovascular and urology drugs and hepatic protectors, among others. It offers cough and cold remedies, …
  • Jiangxi Copper Co Ltd:企業の戦略・SWOT・財務情報
    Jiangxi Copper Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Jiangxi Copper Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Trex Company Inc (TREX):企業の財務・戦略的SWOT分析
    Trex Company Inc (TREX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Codexis Inc (CDXS)-製薬・医療分野:企業M&A・提携分析
    Summary Codexis Inc (Codexis) is a biotechnology company, which focuses on the development of biocatalysts for commercial scale production of fine chemicals and pharmaceuticals. The company’s product portfolio includes pharmaceutical enzymes and intermediates, active pharmaceutical ingredients (APIs …
  • Blue Label Telecoms Ltd (BLU):企業の財務・戦略的SWOT分析
    Blue Label Telecoms Ltd (BLU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Genting Singapore Plc:戦略・SWOT・企業財務分析
    Genting Singapore Plc - Strategy, SWOT and Corporate Finance Report Summary Genting Singapore Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Etihad Aviation Group PJSC:企業の戦略・SWOT・財務情報
    Etihad Aviation Group PJSC - Strategy, SWOT and Corporate Finance Report Summary Etihad Aviation Group PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • H. Lee Moffitt Cancer Center & Research Institute Inc-医療機器分野:企業M&A・提携分析
    Summary H. Lee Moffitt Cancer Center & Research Institute Inc (Moffitt) is a healthcare service provider that concentrates on the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. The center offers medical services suc …
  • AxoGen Inc (AXGN):医療機器:M&Aディール及び事業提携情報
    Summary AxoGen Inc (AxoGen), formerly LecTec Corp is a provider of surgical solutions to measure and monitor nerve functions. The company offers products such as AxoTouch two-point discriminator, AxoGuard nerve connector, Avance nerve graft, AcroVal NSTMS and AxoGuard nerve protector products, among …
  • Costco Wholesale UK Limited:企業の戦略・SWOT・財務分析
    Costco Wholesale UK Limited - Strategy, SWOT and Corporate Finance Report Summary Costco Wholesale UK Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Macmahon Holdings Ltd:企業の戦略・SWOT・財務情報
    Macmahon Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Macmahon Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Akonni Biosystems Inc-医療機器分野:企業M&A・提携分析
    Summary Akonni Biosystems Inc (Akonni Biosystems) is a molecular diagnostics company that develops, manufactures, and distributes integrated molecular diagnostic systems. The company’s products include nucleic acid extraction kits, molecular diagnostic tests, thermal cyclers, microarray readers and …
  • Fresenius Medical Care AG & Co KGaA (FME):企業の財務・戦略的SWOT分析
    Fresenius Medical Care AG & Co KGaA (FME) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Berkshire Hathaway Energy Co-エネルギー分野:企業M&A・提携分析
    Summary Berkshire Hathaway Energy Company (BHE), a subsidiary of Berkshire Hathaway Inc., generates, transmits, stores, distributes, and supplies electricity; and procures, transports, distributes and sells natural gas through its subsidiaries. It generates power through diversified energy sources s …
  • JCR Pharmaceuticals Co Ltd (4552):企業の財務・戦略的SWOT分析
    JCR Pharmaceuticals Co Ltd (4552) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Ebara Corp (6361):企業の財務・戦略的SWOT分析
    Ebara Corp (6361) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Abbott Molecular Inc:医療機器:M&Aディール及び事業提携情報
    Summary Abbott Molecular Inc (Abbott Molecular), formerly Vysis Inc, a subsidiary of Abbott Laboratories, is a medical diagnostics company that provides molecular testing solutions. The company offers infectious disease products, oncology products, genetics products, automation products, molecular d …
  • Acxiom Corp (ACXM):企業の財務・戦略的SWOT分析
    Acxiom Corp (ACXM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆